Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging.

Dorbala, Sharmila;Ando, Yukio;Bokhari, Sabahat;Dispenzieri, Angela;Bourque, Jamieson M;et.al.
(2022) Journal of Cardiac Failure — Vol. 28, n° 7, p. e1-e4 (2022)

Files

2022_Dorbala_J_Card_Fail.pdf
  • Open Access
  • Adobe PDF
  • 72.86 KB
Download

Details

Authors
  • Dorbala, Sharmila
    Author
  • Ando, Yukio
    Author
  • Bokhari, Sabahat
    Author
  • Dispenzieri, Angela
    Author
  • Gheysens, OlivierUCLouvain
    Author
  • Bourque, Jamieson M
    Author
Show more
Abstract
There are 2 primary reasons for an addendum. The first is that the document reviewer list is being updated to include Dr Richard Cheng and Dr Roy John, who have critically reviewed the document, but were inadvertently not listed as reviewers. In addition, since the publication of this document and the introduction of approved therapies for transthyretin cardiac amyloidosis, the clinical use of bone tracer cardiac scintigraphy has been extended to populations with a lower prevalence of transthyretin cardiac amyloidosis. Numerous observations have raised concerns about (1) incorrect diagnosis of transthyretin cardiac amyloidosis based on 99mTc-pyrophosphate (PYP) planar imaging and heart-to-contralateral lung (H/CL) ratio without confirmation of diffuse myocardial uptake on single photon emission computed tomography (SPECT) imaging at some sites; (2) excess blood pool activity on the 1-hour planar and SPECT images being interpreted as positive scans; and (3) missed diagnosis of light chain amyloidosis, as serum-free light chain studies and serum and urine immunofixation electrophoresis studies may not be recommended in the 99mTc-PY P/-3,3-diphosphono-1,2-propanodicarboxylic acid/hydroxymethylene diphosphonate (99mTc-PYP/DPD/HMDP) report. Incorrect diagnosis leads to inappropriate therapy and worse patient outcomes. SPECT and planar imaging performed at 3-hour maximize specificity. 1 , 2 , 3 Additionally, technical parameters have been updated.
Affiliations
  • UZ LeuvenDepartment of Nuclear Medicine

Citations

  • APA
  • Chicago
  • FWB

Dorbala, S., Ando, Y., Bokhari, S., Dispenzieri, A., Falk, R. H., Ferrari, V. A., Fontana, M., Gheysens, O., Gillmore, J. D., Glaudemans, A. W. J. M., Hanna, M. A., Hazenberg, B. P. C., Kristen, A. V., Kwong, R. Y., Maurer, M. S., Merlini, G., Miller, E. J., Moon, J. C., Murthy, V. L., et al. (2022). Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging. Journal of Cardiac Failure, 28(7), e1-e4. https://doi.org/10.1016/j.cardfail.2021.06.012 (Original work published 2022)